Identification of thrombomodulin as a dynamic monitoring biomarker for deep venous thrombosis evolution

Cheng,Xi; Sun,Baolan; Liu,Shiyi; Li,Dandan; Yang,Xiaoqing; Zhang,Yuquan

doi:10.3892/etm.2020.9574

Identification of thrombomodulin as a dynamic monitoring biomarker for deep venous thrombosis evolution

Authors:
- Xi Cheng
- Baolan Sun
- Shiyi Liu
- Dandan Li
- Xiaoqing Yang
- Yuquan Zhang
View Affiliations

Affiliations: Medical College, Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Gynecology and Obstetrics, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: December 14, 2020 https://doi.org/10.3892/etm.2020.9574
Article Number: 142
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been demonstrated that thrombomodulin (TM) serves an important role in the formation of deep venous thrombosis (DVT) and is regarded to be a marker that can be used to measure vascular endothelial cell damage. However, how TM levels change during DVT evolution has not yet been well understood. The current study aimed to investigate the dynamic changes of TM during the evolution of DVT and explore the possible mechanisms behind these. A total of 48 patients newly diagnosed with DVT and 23 matched healthy controls were enrolled in the present study, and their plasma TM levels were examined and compared. In addition, a DVT model was established using Sprague‑Dawley rats via the ‘stenosis’ method. The thrombi size, histopathologic changes and expression of TM and NF‑κB in plasma and venous endothelium were measured at 9 different time points (1, 4, 6, 12 and 24 h, and at 3, 7, 14 and 21 days). Finally, the effect of inhibiting the activation of NF‑κB on TM was investigated using pyrrolidine dithiocarbamate (PDTC), which is a potent inhibitor of the NF‑κB pathway. The results of the current study indicated that the mean level of plasma TM in patients with DVT was significantly increased compared with healthy controls. In addition, thrombi size (clot length and weight), TM and NF‑κB expression in the animal model plasma exhibited three distinct periods (1‑12, 24 h‑day 7 and 14‑21) of markedly different results between periods. Immunofluorescence results confirmed the co‑localization of TM and NF‑κB in endothelial cells. In addition, it was indicated that the expression of TM in the endothelium of DVT models was upregulated compared with the control, while NF‑κB was significantly downregulated. Following the administration of PDTC, the level of NF‑κB and TM in the plasma were decreased significantly dose‑dependently. The results of the current study suggested that TM was involved in the evolution of DVT and may be used as a dynamic biomarker to measure disease activity. Furthermore, the expression of TM during the evolution of DVT was indicated to be associated with the NF‑κB signaling pathway.

View Figures

View References

1	Di Nisio M, van Es N and Büller HR: Deep vein thrombosis and pulmonary embolism. Lancet. 388:3060–3073. 2016.PubMed/NCBI View Article : Google Scholar
2	Thomas M, Hollingsworth A and Mofidi R: Endovascular management of acute lower limb deep vein thrombosis: A systematic review and meta-analysis. Ann Vasc Surg. 58:363–370. 2019.PubMed/NCBI View Article : Google Scholar
3	Galanaud JP, Monreal M and Kahn SR: Epidemiology of the post-thrombotic syndrome. Thromb Res. 164:100–109. 2018.PubMed/NCBI View Article : Google Scholar
4	Shin M, Hino H, Tamura M, Ishizuka B, Tanaka M, Suzuki N and Tateda T: Thrombomodulin improves maternal and fetal conditions in an experimental pre-eclampsia rat model. J Obstet Gynaecol Res. 40:1226–1234. 2014.PubMed/NCBI View Article : Google Scholar
5	Anastasiou G, Gialeraki A, Merkouri E, Politou M and Travlou A: Thrombomodulin as a regulator of the anticoagulant pathway: Implication in the development of thrombosis. Blood Coagul Fibrinolysis. 23:1–10. 2012.PubMed/NCBI View Article : Google Scholar
6	Fu Y, Liu Y, Chen S, Jin Y and Jiang H: The combination of caprini risk assessment scale and thrombotic biomarkers to evaluate the risk of venous thromboembolism in critically ill patients. Medicine (Baltimore). 97(e13232)2018.PubMed/NCBI View Article : Google Scholar
7	Salvagno GL, Pavan C and Lippi G: Rare thrombophilic conditions. Ann Transl Med. 6(342)2018.PubMed/NCBI View Article : Google Scholar
8	Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12(86)2013.PubMed/NCBI View Article : Google Scholar
9	Zhang Q, Lenardo MJ and Baltimore D: 30 Years of NF-κB: A blossoming of relevance to human pathobiology. Cell. 168:37–57. 2017.PubMed/NCBI View Article : Google Scholar
10	Shirai Y, Uwagawa T, Shiba H, Shimada Y, Horiuchi T, Saito N, Furukawa K, Ohashi T and Yanaga K: Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Surgery. 161:1675–1682. 2017.PubMed/NCBI View Article : Google Scholar
11	Ma J and Bai J: Protective effects of heparin on endothelial cells in sepsis. Int J Clin Exp Med. 8:5547–5552. 2015.PubMed/NCBI
12	Wu CT, Chang YH, Lin P, Chen WC and Chen MF: Thrombomodulin expression regulates tumorigenesis in bladder cancer. BMC Cancer. 14(375)2014.PubMed/NCBI View Article : Google Scholar
13	Menschikowski M, Hagelgans A, Tiebel O, Vogel M, Eisenhofer G and Siegert G: Regulation of thrombomodulin expression in prostate cancer cells. Cancer Lett. 322:177–184. 2012.PubMed/NCBI View Article : Google Scholar
14	Song D, Ye X, Xu H and Liu SF: Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood. 114:2521–2529. 2009.PubMed/NCBI View Article : Google Scholar
15	Liang W, Wei F, Yang C, Xie F, Shuai XX, Wang M and Yu M: GDF-15 is associated with thrombus burden in patients with deep venous thrombosis. Thromb Res. 187:148–153. 2020.PubMed/NCBI View Article : Google Scholar
16	Yao X, Chen W, Liu J, Liu H, Zhan JY, Guan S, Lu Z, Tang P, Li P and Lin B: Deep vein thrombosis is modulated by inflammation regulated via sirtuin 1/NF-κB signalling pathway in a rat model. Thromb Haemost. 119:421–430. 2019.PubMed/NCBI View Article : Google Scholar
17	Qin JD, Cao ZH, Li XF, Kang XL, Xue Y, Li YL, Zhang D, Liu XY and Xue YZ: Effect of ammonium pyrrolidine dithiocarbamate (PDTC) on NF-κB activation and CYP2E1 content of rats with immunological liver injury. Pharm Biol. 52:1460–1466. 2014.PubMed/NCBI View Article : Google Scholar
18	Yin J, Wu M, Duan J, Liu G, Cui Z, Zheng J, Chen S, Ren W, Deng J, Tan X, et al: Pyrrolidine dithiocarbamate inhibits NF-KappaB activation and upregulates the expression of Gpx1, Gpx4, occludin, and ZO-1 in DSS-induced colitis. Appl Biochem Biotechnol. 177:1716–1728. 2015.PubMed/NCBI View Article : Google Scholar
19	Zhang Z, Hu L, Chen W, Zhou C, Gui G and Lin B: Danhong huayu koufuye prevents deep vein thrombosis through anti-inflammation in rats. J Surg Res. 201:340–347. 2016.PubMed/NCBI View Article : Google Scholar
20	Diaz JA, Obi AT, Myers DD Jr, Wrobleski SK, Henke PK, Mackman N and Wakefield TW: Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol. 32:556–562. 2012.PubMed/NCBI View Article : Google Scholar
21	Vukojevic J, Siroglavic M, Kasnik K, Kralj T, Stancic D, Kokot A, Kolaric D, Drmic D, Sever AZ, Barisic I, et al: Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. Vascul Pharmacol. 106:54–66. 2018.PubMed/NCBI View Article : Google Scholar
22	Sharma A, Fish BL, Moulder JE, Medhora M, Baker JE, Mader M and Cohen EP: Safety and blood sample volume and quality of a refined retro-orbital bleeding technique in rats using a lateral approach. Lab Anim (NY). 43:63–66. 2014.PubMed/NCBI View Article : Google Scholar
23	Goicoechea M, Cía F, San José C, Asensio A, Emparanza JI, Gil AG, López de Cerain A, Aldazabal P, Azpitarte M, Otaegui D and López de Munain A: Minimizing creatine kinase variability in rats for neuromuscular research purposes. Lab Anim. 42:19–25. 2008.PubMed/NCBI View Article : Google Scholar
24	Bagot CN and Arya R: Virchow and his triad: A question of attribution. Br J Haematol. 143:180–190. 2008.PubMed/NCBI View Article : Google Scholar
25	Iba T and Levy JH: Inflammation and thrombosis: Roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 16:231–241. 2018.PubMed/NCBI View Article : Google Scholar
26	Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J and Rodriguez D: Venous thromboembolism: Thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis. 44:377–385. 2017.PubMed/NCBI View Article : Google Scholar
27	Ochi A, Adachi T, Inokuchi K, Ogawa K, Nakamura Y, Chiba Y, Kawasaki S, Onishi Y, Onuma Y, Munetsugu Y, et al: Effects of aging on the coagulation fibrinolytic system in outpatients of the cardiovascular department. Circ J. 80:2133–2140. 2016.PubMed/NCBI View Article : Google Scholar
28	Bombeli T, Jutzi M, De Conno E, Seifert B and Fehr J: In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins. Blood Coagul Fibrinolysis. 13:577–581. 2002.PubMed/NCBI View Article : Google Scholar
29	Sane M, Granér M, Laukkanen JA, Harjola VP and Mustonen P: Plasma levels of haemostatic factors in patients with pulmonary embolism on admission and seven months later. Int J Lab Hem. 40:66–71. 2018.PubMed/NCBI View Article : Google Scholar
30	Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, et al: Asymptomatic deep vein thrombosis is associated with an increased risk of death: Insights from the APEX trial. Thromb Haemost. 118:2046–2052. 2018.PubMed/NCBI View Article : Google Scholar
31	Kearon C, Comp P, Douketis J, Royds R, Yamada K and Gent M: Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 3:962–968. 2005.PubMed/NCBI View Article : Google Scholar
32	Ayala-Ramírez P, Buitrago T, Poveda A, Rodríguez JL, Olaya-C M and García-Robles R: Increased tissue factor and thrombomodulin expression and histopathological changes in placentas of pregnancies with preeclampsia. J Neonatal Perinatal Med. 9:31–39. 2016.PubMed/NCBI View Article : Google Scholar
33	Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG, Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, et al: NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem. 284:4473–4483. 2009.PubMed/NCBI View Article : Google Scholar
34	Li G, Zhou R, Zhao X, Liu R and Ye C: Correlation between the expression of IL-18 and deep venous thrombosis. Int J Mol Med. 42(2972)2018.PubMed/NCBI View Article : Google Scholar
35	Deng HF, Wang S, Li L, Zhou Q, Guo WB, Wang XL, Liu MD, Liu K and Xiao XZ: Puerarin prevents vascular endothelial injury through suppression of NF-ΚB activation in LPS-challenged human umbilical vein endothelial cells. Biomed Pharmacother. 104:261–267. 2018.PubMed/NCBI View Article : Google Scholar